|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wirth MP, Hakenberg OW and Froehner M:
Antiandrogens in the treatment of prostate cancer. Eur Urol.
51:306–313, discussion 314. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Logan IR, McNeill HV, Cook S, Lu X, Lunec
J and Robson CN: Analysis of the MDM2 antagonist nutlin-3 in human
prostate cancer cells. Prostate. 67:900–906. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Toufektchan E and Toledo F: The guardian
of the genome revisited: p53 downregulates genes required for
telomere maintenance, DNA repair, and centromere structure. Cancers
(Basel). 10:1352018. View Article : Google Scholar
|
|
5
|
Brady CA and Attardi LD: p53 at a glance.
J Cell Sci. 123:2527–2532. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jin L, Li C, Xu Y, Wang L, Liu J, Wang D,
Hong C, Jiang Z, Ma Y, Chen Q and Yu F: Epigallocatechin gallate
promotes p53 accumulation and activity via the inhibition of
MDM2-mediated p53 ubiquitination in human lung cancer cells. Oncol
Rep. 29:1983–1990. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kruse JP and Gu W: SnapShot: p53
posttranslational modifications. Cell. 133:930–30.e1. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Muñoz-Fontela C, González D, Marcos-Villar
L, Campagna M, Gallego P, González-Santamaría J, Herranz D, Gu W,
Serrano M, Aaronson SA and Rivas C: Acetylation is indispensable
for p53 antiviral activity. Cell Cycle. 10:3701–3705. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sakaguchi K, Herrera JE, Saito S, Miki T,
Bustin M, Vassilev A, Anderson CW and Appella E: DNA damage
activates p53 through a phosphorylation-acetylation cascade. Genes
Dev. 12:2831–2841. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jimenez GS, Khan SH, Stommel JM and Wahl
GM: p53 regulation by post-translational modification and nuclear
retention in response to diverse stresses. Oncogene. 18:7656–7665.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee JT and Gu W: The multiple levels of
regulation by p53 ubiquitination. Cell Death Differ. 17:86–92.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yuan J, Luo K, Zhang L, Cheville JC and
Lou Z: USP10 regulates p53 localization and stability by
deubiquitinating p53. Cell. 140:384–396. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Olivier M, Hollstein M and Hainaut P: TP53
mutations in human cancers: Origins, consequences, and clinical
use. Cold Spring Harb Perspect Biol. 2:a0010082010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Robles AI and Harris CC: Clinical outcomes
and correlates of TP53 mutations and cancer. Cold Spring Harb
Perspect Biol. 2:a0010162010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Leite KR, Franco MF, Srougi M, Nesrallah
LJ, Nesrallah A, Bevilacqua RG, Darini E, Carvalho CM, Meirelles
MI, Santana I and Camara-Lopes LH: Abnormal expression of MDM2 in
prostate carcinoma. Mod Pathol. 14:428–436. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bohlman S and Manfredi JJ: p53-independent
effects of Mdm2. Subcell Biochem. 85:235–246. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Alarcon-Vargas D and Ronai Z: p53-Mdm2 -
the affair that never ends. Carcinogenesis. 23:541–547. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nag S, Qin J, Srivenugopal KS, Wang M and
Zhang R: The MDM2-p53 pathway revisited. J Biomed Res. 27:254–271.
2013.PubMed/NCBI
|
|
19
|
Moll UM and Petrenko O: The MDM2-p53
interaction. Mol Cancer Res. 1:1001–1008. 2003.PubMed/NCBI
|
|
20
|
Khan N, Bharali DJ, Adhami VM, Siddiqui
IA, Cui H, Shabana SM, Mousa SA and Mukhtar H: Oral administration
of naturally occurring chitosan-based nanoformulated green tea
polyphenol EGCG effectively inhibits prostate cancer cell growth in
a xenograft model. Carcinogenesis. 35:415–423. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Robson CH, Ganapathy M, Swanson GP,
Natarajan M, Papanikolaou N, Hanes MA, Yeh IT, Ghosh R and Kumar
AP: Phellodendron amurense bark extract enhances radiosensitivity
by inhibition of nf-kappa B in transgenic adenocarcinoma of mouse
prostate model and human prostate cancer cells. J Urol. 181((4S)):
4792009. View Article : Google Scholar
|
|
22
|
Paller CJ, Pantuck A and Carducci MA: A
review of pomegranate in prostate cancer. Prostate Cancer Prostatic
Dis. 20:265–270. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Seeram NP, Adams LS, Henning SM, Niu Y,
Zhang Y, Nair MG and Heber D: In vitro antiproliferative, apoptotic
and antioxidant activities of punicalagin, ellagic acid and a total
pomegranate tannin extract are enhanced in combination with other
polyphenols as found in pomegranate juice. J Nutr Biochem.
16:360–367. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Han DH, Lee MJ and Kim JH: Antioxidant and
apoptosis-inducing activities of ellagic acid. Anticancer Res.
26:3601–3606. 2006.PubMed/NCBI
|
|
25
|
Naiki-Ito A, Chewonarin T, Tang M,
Pitchakarn P, Kuno T, Ogawa K, Asamoto M, Shirai T and Takahashi S:
Ellagic acid, a component of pomegranate fruit juice, suppresses
androgen-dependent prostate carcinogenesis via induction of
apoptosis. Prostate. 75:151–160. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Losso JN, Bansode RR, Trappey A II, Bawadi
HA and Truax R: In vitro anti-proliferative activities of ellagic
acid. J Nutr Biochem. 15:672–678. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Malik A, Afaq S, Shahid M, Akhtar K and
Assiri A: Influence of ellagic acid on prostate cancer cell
proliferation: A caspase-dependent pathway. Asian Pac J Trop Med.
4:550–555. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vanella L, Di Giacomo C, Acquaviva R,
Barbagallo I, Cardile V, Kim DH, Abraham NG and Sorrenti V:
Apoptotic markers in a prostate cancer cell line: Effect of ellagic
acid. Oncol Rep. 30:2804–2810. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vanella L, Di Giacomo C, Acquaviva R,
Barbagallo I, Li Volti G, Cardile V, Abraham NG and Sorrenti V:
Effects of ellagic acid on angiogenic factors in prostate cancer
cells. Cancers (Basel). 5:726–738. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang L, Li W, Lin M, Garcia M, Mulholland
D, Lilly M and Martins-Green M: Luteolin, ellagic acid and punicic
acid are natural products that inhibit prostate cancer metastasis.
Carcinogenesis. 35:2321–2330. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang HM, Zhao L, Li H, Xu H, Chen WW and
Tao L: Research progress on the anticarcinogenic actions and
mechanisms of ellagic acid. Cancer Biol Med. 11:92–100.
2014.PubMed/NCBI
|
|
32
|
Mohammed Saleem YI, Albassam H and Selim
M: Urolithin A induces prostate cancer cell death in p53-dependent
and in p53-independent manner. Eur J Nutr. 59:1607–1618. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Van Dross RT: Metabolism of anandamide by
COX-2 is necessary for endocannabinoid-induced cell death in
tumorigenic keratinocytes. Mol Carcinog. 48:724–732. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nelly Etienne-Selloum ID, Tanveer Sharif
CAa and Schini-Kerth VB: Polyphenolic Compounds Targeting
p53-Family Tumor Suppressors. Current Progress and Challenges.
2013.
|
|
36
|
Khoo KH, Verma CS and Lane DP: Drugging
the p53 pathway: Understanding the route to clinical efficacy. Nat
Rev Drug Discov. 13:217–236. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ceci C, Lacal PM, Tentori L, De Martino
MG, Miano R and Graziani G: Experimental evidence of the antitumor,
antimetastatic and antiangiogenic activity of ellagic acid.
Nutrients. 10:17562018. View Article : Google Scholar
|
|
38
|
Loughery J, Cox M, Smith LM and Meek DW:
Critical role for p53-serine 15 phosphorylation in stimulating
transactivation at p53-responsive promoters. Nucleic Acids Res.
42:7666–7680. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Agrawal A, Yang J, Murphy RF and Agrawal
DK: Regulation of the p14ARF-Mdm2-p53 pathway: An overview in
breast cancer. Exp Mol Pathol. 81:115–122. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shukla S and Gupta S: Apigenin-induced
prostate cancer cell death is initiated by reactive oxygen species
and p53 activation. Free Radic Biol Med. 44:1833–1845. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Aliouat-Denis CM, Dendouga N, Van den
Wyngaert I, Goehlmann H, Steller U, van de Weyer I, Van Slycken N,
Andries L, Kass S, Luyten W, et al: p53-independent regulation of
p21Waf1/Cip1 expression and senescence by Chk2. Mol Cancer Res.
3:627–634. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang Z, Wang H, Li M, Agrawal S, Chen X
and Zhang R: MDM2 is a negative regulator of p21WAF1/CIP1,
independent of p53. J Biol Chem. 279:16000–16006. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kracikova M, Akiri G, George A,
Sachidanandam R and Aaronson SA: A threshold mechanism mediates p53
cell fate decision between growth arrest and apoptosis. Cell Death
Differ. 20:576–588. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Meek DW and Knippschild U:
Posttranslational modification of MDM2. Mol Cancer Res.
1:1017–1026. 2003.PubMed/NCBI
|
|
45
|
Seeram NP, Lee R and Heber D:
Bioavailability of ellagic acid in human plasma after consumption
of ellagitannins from pomegranate (Punica granatum L.)
juice. Clin Chim Acta. 348:63–68. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Bell C and Hawthorne S: Ellagic acid,
pomegranate and prostate cancer-a mini review. J Pharm Pharmacol.
60:139–144. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bala I, Bhardwaj V, Hariharan S, Kharade
SV, Roy N and Ravi Kumar MN: Sustained release nanoparticulate
formulation containing antioxidant-ellagic acid as potential
prophylaxis system for oral administration. J Drug Target.
14:27–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jeong YI, Prasad Yv R, Ohno T, Yoshikawa
Y, Shibata N, Kato S, Takeuchi K and Takada K: Application of
Eudragit P-4135F for the delivery of ellagic acid to the rat lower
small intestine. J Pharm Pharmacol. 53:1079–1085. 2001. View Article : Google Scholar : PubMed/NCBI
|
